Pharmaceutical Executive

🚨Our March issue is LIVE🚨 Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right here➡️pharmexec.com/journals/pharm…

More time. More opportunity. The 2026 Emerging Pharma Leaders Awards deadline has been extended to May 1st 🎉 ➡️Don’t miss your chance to recognize the industry’s rising stars: hubs.li/Q047Mlzx0 #PharmExec #EmergingPharmaLeaders #BGBGroup

Access and affordability challenges don’t stop at launch. Explore lifecycle strategies that reduce barriers, support providers, and improve adherence from launch to loss of exclusivity: hubs.li/Q045nwJh0 #PatientAccess

Do you know someone driving pharma forward? 🌟 Nominations are open for the 2026 Emerging Pharma Leaders Awards, sponsored by BGB Group! Nominate a rising star before the April 8th deadline: hubs.ly/Q047c98K0 #PharmExec #EmergingLeadersAwards #BGBGroup

🚨 PE Spotlight: The U.S. Food and Drug Administration expanded approval of Arexvy from GSK to adults 18–49 at higher risk for severe Respiratory Syncytial Virus Infection. 🔗 See what the expanded approval means for RSV prevention: hubs.li/Q046YrRR0 #PharmExec #PESpotlight #TrendinginPharma

The shift from “I think” to “I know” changes everything. See how leading organizations turn uncertainty into clarity with validated patient data that strengthens every strategic move. Watch Episode 5: hubs.li/Q03YZsGS0 #PharmaInnovation #ConfidentDecisions

🚨 PE Spotlight: A survey from the West Health-Gallup Center found 1 in 3 Americans cut back on essentials like food or utilities to pay for healthcare—affecting more than 80 million people. 🔗 Find out more: hubs.li/Q046MTsw0 #PharmExec #PESpotlight #TrendinginPharma

🚨 PE Spotlight Eli Lilly has issued a warning about potential safety risks linked to compounded versions of tirzepatide mixed with vitamin B12. Read more: 🔗 hubs.li/Q046CBhN0 #PESpotlight

Do you know someone creating meaningful change in pharma? Nominations are open for the Emerging Pharma Leaders Awards, sponsored by BGB Group. 🗓 Deadline: April 18 Submit your nomination: hubs.li/Q046mkrt0 #PharmExec #BGBGroup #EmergingPharmaLeaders

🚨 PE Spotlight The U.S. Food and Drug Administration has approved Leucovorin as the first treatment for Cerebral Folate Deficiency. Notably, the decision relied on literature reviews and case reports rather than new clinical trials. Read more: 🔗 hubs.li/Q046f4kw0 #PESpotlight #TrendingPharma

🚨 PE Spotlight: Vinay Prasad Out at CBER for Second Time in Under a Year Vinay Prasad is stepping down from the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration for the second time in under a year. 🔗 Read the full PE Spotlight: hubs.li/Q0462J2J0 #PESpotlight #PharmExec #TrendinginPharma #FDA #Biotech

🚨 PE Spotlight: Pharma Funding Roundup Cognito Therapeutics closed an oversubscribed $105M Series C to advance its Alzheimer’s therapy, while NexCure launched with $19M in Series A funding to expand CAR-T access. What do these investments signal for the future of biotech innovation? 🔗 Read more: hubs.li/Q045SYkZ0 #PharmExec #PESpotlight #Biotech #Pharma #Alzheimers #CART

🚨 PE Spotlight: Trending Pharma - AI is everywhere in life sciences, but where is it actually delivering? Watch Peter Young chat with Najat Khan, PhD, CEO of Recursion Pharmaceuticals, on AI in drug discovery, development, and manufacturing on this Pharmaceutical Executive Academy broad forum. 📽️Watch the full discussion: hubs.li/Q045LfW30 #PESpotlight #TrendingPharma #PharmExecAcademy

🚨 PE Spotlight: Is governed, transparent AI the key to faster drug development? Leaders from CausaLens and eClinical Solutions discuss audit-ready “glass box” AI, compliance-by-design workflows, and the future of regulator-inspectable decisions. Read more: hubs.li/Q045DsKC0 #PharmExec #PESpotlight #AI #Pharma #DrugDevelopment

Pharma cold chain is going circular—reducing cost, CO₂, and waste without sacrificing performance. See how recycled-content packaging is changing the model: hubs.li/Q042S4t10 #ColdChain

🚨 PE Spotlight: Bavarian Nordic CEO Paul Chaplin plans to step down by end of 2026. A formal search is underway as he remains in role to ensure continuity after transforming the company into a profitable global vaccine player. What should the next CEO prioritize? Read more: hubs.li/Q045rJHW0 #PharmExec #PESpotlight #Biotech #Vaccines

🚨 PE Spotlight: The FDA expanded approval of BioMarin Pharmaceutical Inc.’s Palynziq to include patients 12+ with PKU. A big move for treatment access. What’s the impact for rare disease care? 🔗 Read more: hubs.li/Q045dNx80 #PharmExec #PESpotlight #TrendinginPharma

Guesswork comes at a cost. Discover how defensible data helps pharma teams align faster, build internal trust, and gain a competitive edge in the market. Watch Episode 4: hubs.li/Q03YZsyN0 #PharmaCommercial #DecisionMaking

🚨 PE Spotlight Boehringer Ingelheim has secured an exclusive license from Sitryx Therapeutics for a preclinical small-molecule program targeting immune pathways. 🔗Read more: hubs.li/Q0453h970 #PharmExec #PESpotlight #TrendingPharma

🚨 PE Spotlight: Leading in the Psychedelic Space with Tarek Rabah In this exclusive Q&A, Otsuka America Pharmaceutical CEO Tarek Rabah shares how the company is investing early in psychedelic-inspired R&D and advancing new approaches for depression and PTSD. Read more: hubs.li/Q044X02V0 #PESpotlight #PharmExec #PharmaLeadership #MentalHealthInnovation #Psychedelics

🚨 PE Spotlight: Trending Pharma The FDA has approved Braftovi + Erbitux for adults with BRAF V600E-mutant metastatic colorectal cancer after prior therapy. 🔗 Read more: hubs.li/Q044J63Y0 #PharmExec #PESpotlight